Biosynthesis of Cannabinoids Market is Rising Data Analysis Worldwide Forecast 2030 - Benzinga
INM Stock | USD 4.00 1.05 20.79% |
About 62% of InMed Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading InMed Pharmaceuticals stock suggests that many investors are alarmed at this time. InMed Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in InMed Pharmaceuticals. Many technical investors use InMed Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
InMed |
Biosynthesis of Cannabinoids Market is Rising Data Analysis Worldwide Forecast 2030 Benzinga
Read at news.google.com
InMed Pharmaceuticals Fundamental Analysis
We analyze InMed Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InMed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InMed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
InMed Pharmaceuticals is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
InMed Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with InMed Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of InMed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing InMed Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
InMed Pharmaceuticals Related Equities
TNXP | Tonix Pharmaceuticals | 33.33 | ||||
SONN | Sonnet Biotherapeutics | 29.87 | ||||
NBY | NovaBay Pharmaceuticals | 14.08 | ||||
VRAX | Virax Biolabs | 2.39 | ||||
IMMX | Immix Biopharma | 0.51 | ||||
QNRX | Quoin Pharmaceuticals | 3.28 | ||||
ATNF | 180 Life | 3.29 | ||||
ALLR | Allarity Therapeutics | 3.81 | ||||
GOVX | GeoVax Labs | 4.95 | ||||
PALI | Palisade Bio | 5.30 | ||||
ZVSA | ZyVersa Therapeutics | 5.41 | ||||
BDRX | Biodexa Pharmaceticals | 5.45 | ||||
ICU | LMF Acquisition | 5.71 | ||||
DRUG | Bright Minds | 6.03 | ||||
PHIO | Phio Pharmaceuticals | 7.66 | ||||
REVB | Revelation Biosciences | 14.63 |
Check out InMed Pharmaceuticals Hype Analysis, InMed Pharmaceuticals Correlation and InMed Pharmaceuticals Performance. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.